We are live on ! Find out more
KIN

Kindred Biosciences, Inc.
KIN

Delisted

KIN was delisted on the 27th of August, 2021.

75 hedge funds and large institutions have $220M invested in Kindred Biosciences, Inc. in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

25% more capital invested

Capital invested by funds: $177M → $220M (+$43.8M)

24% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 17

4% more funds holding

Funds holding: 7275 (+3)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
75
Holders Change
+3
Holders Change %
+4.17%
% of All Funds
1.48%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
11
Increased
21
Reduced
17
Closed
7
Calls
$156K
Puts
Net Calls
+$156K
Net Calls Change
-$241K
Name Holding Trade Value Shares
Change
Change in
Stake
FG
26
Formula Growth
Quebec, Canada
$594K
OWD
27
Osborn Williams & Donohoe
Ohio
$532K
California Public Employees Retirement System
28
California Public Employees Retirement System
California
$503K +$463K +59,300 New
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$484K
State of Wisconsin Investment Board
30
State of Wisconsin Investment Board
Wisconsin
$471K
RhumbLine Advisers
31
RhumbLine Advisers
Massachusetts
$407K +$2.57K +329 +0.7%
Millennium Management
32
Millennium Management
New York
$401K -$103K -13,141 -22%
WG
33
Winton Group
United Kingdom
$369K -$113K -14,479 -25%
Squarepoint
34
Squarepoint
New York
$348K +$210K +26,863 +189%
Barclays
35
Barclays
United Kingdom
$314K +$145K +18,538 +100%
TA
36
Teton Advisors
New York
$305K
NSEDCP
37
NJ State Employees Deferred Compensation Plan
New Jersey
$271K
AllianceBernstein
38
AllianceBernstein
Tennessee
$265K
Cambridge Investment Research Advisors
39
Cambridge Investment Research Advisors
Iowa
$263K +$242K +31,050 New
Goldman Sachs
40
Goldman Sachs
New York
$238K -$905K -116,005 -80%
MIM
41
MetLife Investment Management
New Jersey
$213K
Edgewood Management
42
Edgewood Management
Connecticut
$212K +$195K +25,000 New
Manulife (Manufacturers Life Insurance)
43
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$201K -$13.4K -1,711 -7%
AIG
44
American International Group
New York
$197K -$1.53K -196 -0.8%
Prudential Financial
45
Prudential Financial
New Jersey
$164K +$151K +19,329 New
VOYA Investment Management
46
VOYA Investment Management
Georgia
$157K +$28.6K +3,669 +25%
AQR Capital Management
47
AQR Capital Management
Connecticut
$151K
Bank of America
48
Bank of America
North Carolina
$147K +$9.5K +1,217 +8%
EAM
49
Evanson Asset Management
California
$140K
GF
50
Gabelli Funds
New York
$136K

KIN Hedge Fund Activity: Q4 2019 in Review

75 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q4 2019, worth a combined $220M — up 25% from $177M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new KIN positions and 7 closed out — a net gain of 4 holders — while 21 added to existing stakes and 17 trimmed.

The largest buyer was California Public Employees Retirement System, opening a new position worth an estimated $463K. The largest seller was Ariel Investments, cutting an estimated $975K.

  • 75 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q4 2019, up from 72 in Q3 2019.
  • Funds reported $220M of Kindred Biosciences, Inc. stock for Q4 2019, up 25% quarter-over-quarter.
  • 11 funds opened new Kindred Biosciences, Inc. positions in Q4 2019 and 7 closed out, a net change of +4 holders.
  • The largest Kindred Biosciences, Inc. buyer in Q4 2019 was California Public Employees Retirement System, an estimated $463K added.
  • The largest Kindred Biosciences, Inc. seller in Q4 2019 was Ariel Investments, an estimated $975K sold.

Based on aggregated 13F filings for Q4 2019.